biotech
biotech Articles
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
Published:
Last Updated:
A letter from the FDA citing deficiencies in its treatment for moderate to severe dysparaeunia due to vulvar vaginal atrophy had a negative impact on TherapeuticsMD stock, but it was not a death...
Published:
Last Updated:
Cytori Therapeutics saw its shares explode after it was reported that the firm received approval from the FDA for its treatment of thermal burn injuries.
Published:
Last Updated:
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
Published:
Last Updated:
There is absolutely no denial that a marijuana ETF will generate some investor interest. While this may be a first for true ETF investors, unfortunately many U.S. investors might have a very hard...
Published:
Last Updated:
Catalyst Biosciences watched its shares fall on Friday following the announcement of a secondary offering.
Published:
Last Updated:
Neothetics saw its stock hit a multiyear high on Wednesday after the firm announced a critical patent approval.
Published:
Last Updated:
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial.
Published:
Last Updated:
The road to a pivotal Phase 3 trial usually takes years following an IPO, but Therapix Biosciences may reach that stage in just a few months' time.
Published:
Last Updated:
Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial public offering valued up to about $100 million.
Published:
Last Updated:
NovoCure saw its shares skyrocket early on Monday after the firm provided an update for its late-stage cancer trial.
Published:
Last Updated:
Shares of Akari Therapeutics saw a handy gain on Friday after the firm announced that the FDA granted a Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria.
Published:
Last Updated:
A few biopharma stocks made massive runs on Tuesday morning as the result of clinical trial results and earnings. Although not all of these moves were positive the overall sentiment was positive.
Published:
Last Updated:
Catalyst Biosciences saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval.
Published:
Last Updated:
The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of the ACA fell through, the health care rally is called into question.
Published:
Last Updated: